Waleed H. Hassanein Sells 30,000 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $130.07, for a total value of $3,902,100.00. Following the completion of the sale, the chief executive officer now directly owns 61,643 shares in the company, valued at $8,017,905.01. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

TransMedics Group Stock Performance

TransMedics Group stock traded down $0.06 during midday trading on Wednesday, hitting $127.22. The stock had a trading volume of 637,458 shares, compared to its average volume of 769,221. The company has a market capitalization of $4.19 billion, a PE ratio of -374.35 and a beta of 1.87. The company has a current ratio of 9.72, a quick ratio of 8.76 and a debt-to-equity ratio of 3.18. The firm’s fifty day moving average is $87.41 and its two-hundred day moving average is $78.57. TransMedics Group, Inc. has a 52-week low of $36.42 and a 52-week high of $132.96.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.40. The firm had revenue of $96.90 million during the quarter, compared to analyst estimates of $83.78 million. TransMedics Group had a positive return on equity of 7.95% and a negative net margin of 3.43%. The business’s quarterly revenue was up 132.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.08) earnings per share. On average, research analysts forecast that TransMedics Group, Inc. will post 0.62 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Piper Sandler reissued an “overweight” rating and issued a $120.00 target price (up from $95.00) on shares of TransMedics Group in a research note on Wednesday, May 1st. TD Cowen lifted their target price on shares of TransMedics Group from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Morgan Stanley increased their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, February 28th. JPMorgan Chase & Co. lifted their target price on TransMedics Group from $105.00 to $127.00 and gave the stock an “overweight” rating in a report on Wednesday, May 1st. Finally, Canaccord Genuity Group upped their price target on TransMedics Group from $102.00 to $117.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, TransMedics Group presently has a consensus rating of “Moderate Buy” and an average price target of $119.00.

Institutional Trading of TransMedics Group

Several institutional investors have recently added to or reduced their stakes in TMDX. FMR LLC raised its stake in shares of TransMedics Group by 42.5% during the third quarter. FMR LLC now owns 4,714,870 shares of the company’s stock valued at $258,139,000 after acquiring an additional 1,407,171 shares in the last quarter. Eventide Asset Management LLC grew its position in TransMedics Group by 1,271.7% during the third quarter. Eventide Asset Management LLC now owns 925,356 shares of the company’s stock valued at $50,663,000 after buying an additional 857,895 shares during the period. Mackenzie Financial Corp purchased a new position in TransMedics Group in the fourth quarter valued at $35,804,000. Wasatch Advisors LP acquired a new position in shares of TransMedics Group in the first quarter worth about $32,162,000. Finally, Bank of New York Mellon Corp grew its position in shares of TransMedics Group by 91.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 760,099 shares of the company’s stock valued at $41,615,000 after acquiring an additional 363,012 shares during the period. Institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.